ÁÖÀǷ°áÇÌ °úÀ×ÇൿÀå¾Ö ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2024-2032³â)
Attention Deficit Hyperactivity Disorder Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
»óǰÄÚµå : 1638733
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÁÖÀǷ°áÇÌ °úÀ×ÇൿÀå¾Ö ½ÃÀåÀº 2023³â 158¾ï ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 5.1% ÀÌ»ó ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀº ÁÖ·Î ADHD Áø´ÜÀÇ Áõ°¡, Áø´Ü µµ±¸ÀÇ ¹ßÀü, Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ Áö¼ÓÀûÀÎ °³¹ß, ADHD¿¡ ´ëÇÑ Àνİú ÀÌÇØ°¡ ³ô¾ÆÁö¸é¼­ Áø´Ü ¹× Ä¡·á ¿É¼Ç °­È­¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù.

ADHD´Â ºÎÁÖÀÇ, °úÀ×Çൿ, Ãæµ¿¼º µîÀÇ Áõ»óÀ» Ư¡À¸·Î ÇÏ´Â ½Å°æ¹ß´ÞÀå¾Ö·Î ¾î¸°À̺ÎÅÍ ¼ºÀαîÁö ´Ù¾çÇÑ ¿¬·ÉÃþ¿¡¼­ ¹ßº´Çϸç, ADHD ½ÃÀåÀº Áø´Ü, Ä¡·á, °ü¸® Àü·«, ¾à¹° Ä¡·á, Çൿ ÁßÀç, Áø´Ü µµ±¸, Áö¿ø ¼­ºñ½º µîÀ» ÅëÇØ ´Ù¾çÇÑ ¿¬·É´ëÀÇ È¯ÀÚµéÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Ä¡·á ¿É¼ÇÀº ´Ù¾çÇϸç, ¾à¸®ÇÐÀû Á¢±Ù°ú ºñ¾à¸®ÇÐÀû Á¢±ÙÀ» ¸ðµÎ Æ÷ÇÔÇϸç, ÀÚ±ØÁ¦¿Í ºñÀÚ±ØÁ¦°¡ ÁÖ¿ä ¼Ö·ç¼Ç Áß ÇϳªÀÔ´Ï´Ù.

ADHD Ä¡·áÁ¦ ½ÃÀå¿¡¼­´Â °¢¼ºÁ¦°¡ ¸ÅÃâÀÇ ´ëºÎºÐÀ» Â÷ÁöÇϸç 2023³â 112¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ÀÌµé ¾à¹°Àº ³úÀÇ ³ë¸£¿¡Çdz×ÇÁ¸°°ú µµÆÄ¹Î ¼öÄ¡¸¦ Áõ°¡½ÃÄÑ ÁÖÀÇ·Â, ÁýÁß·Â, Ãæµ¿ Á¶ÀýÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. °¢¼ºÁ¦´Â Áï°¢ÀûÀÎ È¿°ú·Î ÀÎÇØ ADHD Ä¡·áÀÇ ±âÃʰ¡ µÇÁö¸¸, ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀ» °ü¸®Çϰí È¿°ú¸¦ Áö¼Ó½Ã۱â À§Çؼ­´Â °³º°È­µÈ Ä¡·á °èȹ°ú Àå±âÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇʼöÀûÀÔ´Ï´Ù. ºñÀڱؼº ¾à¹°Àº ÀϹÝÀûÀ¸·Î È¿°ú°¡ ¶³¾îÁöÁö¸¸, ´Ù¸¥ Á¢±Ù¹ýÀ» ¿øÇϴ ȯÀÚ¿¡°Ô´Â ´ë¾ÈÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2023³â
¿¹Ãø ¿¬µµ 2024-2032³â
½ÃÀÛ ±Ý¾× 158¾ï ´Þ·¯
¿¹»ó ±Ý¾× 246¾ï ´Þ·¯
CAGR 5.1%

½ÃÀåÀº ¿¬·É´ëº°·Î ±¸ºÐµÇ¸ç, 2023³â¿¡´Â ¾Æµ¿ÀÌ 67.1%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ADHD ¾Æµ¿ÀÇ °æ¿ì Á¶±â Áø´Ü°ú ¸ÂÃãÇü °³ÀÔÀÌ ÇʼöÀûÀ̸ç, Çо÷ ¹× »çȸ¼º ¹ß´Þ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. ÁßÀç¿¡´Â Çൿ Ä¡·á, ±³À° Áö¿ø, Çʿ信 µû¶ó ¾à¹° Ä¡·á µîÀÌ Æ÷ÇԵ˴ϴÙ.

¼ºº°·Î´Â ³²¼ºÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, °úÀ×Çൿ°ú Ãæµ¿ÀûÀÎ ÇൿÀÌ µÎµå·¯Áö±â ¶§¹®¿¡ Áø´ÜÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº À¯º´·üÀº ±³À° ¹× »çȸ ȯ°æ¿¡¼­ ³²¼ºÀÌ Á¾Á¾ Á÷¸éÇϴ ƯÀ¯ÀÇ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇÑ Ç¥ÀûÈ­µÈ Ä¡·á Á¢±Ù¹ýÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Á¦Çü Áß Á¤Á¦°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç 2023³â¿¡´Â 92¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ¼Ó¹æ¼º ¹× ¼­¹æ¼º Á¦Á¦¸¦ Æ÷ÇÔÇÑ Á¤Á¦´Â ¼Ò¾ÆºÎÅÍ ¼ºÀαîÁö ´Ù¾çÇÑ ¿¬·ÉÃþÀÌ À¯¿¬ÇÏ°Ô º¹¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¼Ò¸Å ¾à±¹Àº ADHD Ä¡·áÁ¦ À¯Åë¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ÆíÀǼº, Á¤±âÀûÀΠó¹æÀü º¸Ãæ, º¸Çè °ü¸® Áö¿ø µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ 93¾ï ´Þ·¯ ±Ô¸ðÀÇ ½ÃÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ ADHD ½ÃÀåÀº ¿¬Æò±Õ 5.1%ÀÇ ¼ºÀå·üÀ» º¸À̸ç 2032³â 102¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¿øµ¿·ÂÀº ³ôÀº ÀÎÁöµµ, Ä¡·á¿¡ ´ëÇÑ º¸Çè Àû¿ë, µðÁöÅÐ Ä¡·á ¿É¼ÇÀÇ Çõ½ÅÀ¸·Î ½ÃÀå ±âȸ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¾à¹° À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¿¬·ÉÃþº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¼ºº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Á¦Çüº°, 2021-2032³â

Á¦9Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

Á¦10Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦11Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Attention Deficit Hyperactivity Disorder Market reached a valuation of USD 15.8 billion in 2023 and is anticipated to expand at a CAGR of over 5.1% from 2024 to 2032. This growth is primarily driven by increasing ADHD diagnoses, advancements in diagnostic tools, and the continuous development of innovative treatments. Rising awareness and understanding of ADHD are also contributing factors, leading to greater demand for enhanced diagnosis and treatment options.

ADHD, a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity, affects both children and adults. The ADHD market covers diagnosis, treatment, and management strategies, offering pharmaceutical therapies, behavioral interventions, diagnostic tools, and support services to improve patient outcomes across age groups. Treatment options are diverse, encompassing both pharmacological and non-pharmacological approaches, with stimulant and non-stimulant medications among the primary solutions.

In the ADHD drug market, stimulants account for the majority of sales, valued at USD 11.2 billion in 2023. These medications work by increasing norepinephrine and dopamine levels in the brain, helping improve attention, focus, and impulse control. While stimulants have become a foundational part of ADHD treatment due to their rapid effectiveness, individualized treatment plans and long-term monitoring are essential to manage potential side effects and ensure sustained benefits. Non-stimulant options, though generally less effective, provide alternatives for patients seeking different approaches.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$15.8 Billion
Forecast Value$24.6 Billion
CAGR5.1%

The market is segmented by age group, with children representing a substantial share of 67.1% in 2023. Early diagnosis and tailored interventions are vital for children with ADHD, helping them address challenges that impact their academic and social development. Interventions may include behavioral therapy, educational support, and medication as needed.

Gender-wise, males lead the market, with a significant portion of diagnoses due to the more visible nature of hyperactive and impulsive behaviors. This higher prevalence has spurred targeted treatment approaches to address the unique challenges males often face in educational and social environments.

Among dosage forms, tablets hold the largest market share, reaching USD 9.2 billion in 2023. Tablets, including immediate-release and extended-release formulations, allow flexible dosing for both children and adults. Retail pharmacies play a critical role in distributing ADHD medications, contributing USD 9.3 billion to the market, with benefits including convenience, regular prescription refills, and insurance management support.

In the U.S., the ADHD market is expected to grow at a 5.1% CAGR, reaching USD 10.2 billion by 2032. This growth is driven by high awareness, insurance coverage for treatments, and innovations in digital therapeutic options, enhancing market opportunities.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates & Forecast, By Drug Type, 2021-2032 ($ Mn)

Chapter 6 Market Estimates & Forecast, By Age Group, 2021-2032 ($ Mn)

Chapter 7 Market Estimates & Forecast, By Gender, 2021-2032 ($ Mn)

Chapter 8 Market Estimates & Forecast, By Dosage Form, 2021-2032 ($ Mn)

Chapter 9 Market Estimates & Forecast, By Distribution Channel, 2021-2032 ($ Mn)

Chapter 10 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

Chapter 11 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â